List of Small Molecule Pharmaceuticals Companies in Connecticut - 26

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

BiologicsMD is developing novel therapeutics and therapeutic-device combinations for the treatment of hair-loss and bone disorders. The company's portfolio of hair cycle stimulators (HCS) are first-in-class treatments that hold the promise to restore hair and prevent hair loss in conditions of alopecia. The core technology relies on targeting physiologically active agents to Type l collagen found in skin and bone. BiologicsMD's targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

CheminPharma is a biotechnology services company based in Woodbridge, CT. Founded in 2007, the main objective is to provide high-quality medicinal chemistry focused drug discovery services to biotechnology and pharmaceutical sector. In recent years, CheminPharma has expanded into other closely related businesses. CheminPharma's business rests on the following two pillar strategies: 1. Drug discovery research services 2. Novel Research tools & reagents We are looking to form partnerships with small molecule biotechnology and pharmaceutical companies where we can provide essential chemistry services to aid in the drug discovery process. If you are interested in a collaboration opportunity, feel free to contact us directly!

LEADING THE SUPPLY OF HIGH QUALITY GENERIC APIs 21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality API's to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection, development, analytical and regulatory services, and strong project management to ensure the highest standards of quality. We are committed to providing our customers with a distinct competitive advantage. Our team of technical, analytical, regulatory and marketing experts can enhance your business by: 1. Advancing your product development; 2. Ensuring the manufacturing facilities we represent maintain a high level of compliance with ever-evolving cGMPs; 3. Collaborating with manufacturers in establishing appropriate protocols and methodologies to prepare a sound and complete DMF; 4. Sourcing APIs from China, India, Germany and the US to provide our customers with the best value; and 5. Advancing Paragraph IV filings through our exclusive API development and supply partnerships.

Cytogel is a clinical stage bio-pharmaceutical company developing first in class drug candidates from the novel endomorphin family of molecules, that target key pain pathways and alleviate pain. This groundbreaking approach is backed by new technology to deliver treatment to people in pain. Learn how we’re reinventing pain management.

DKP Genomics is a bioinformatics CRO. We provide top-quality computational biology analysis and bioinformatics infrastructure support to biotechnology, pharma, and agricultural companies and to research foundations. With nearly 15 years of experience in both biotech and major pharma, we're well versed in the standard analyses as well as advanced analyses to help identify targets, biomarkers, compound mechanisms, and advance the understanding of biological pathways and systems in multiple areas: microbial systems, diabetes / obesity, frailty, cancer, and neuroscience. More information can be found at http://www.dkpgenomics.com

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today's precision cancer medicines. Using a novel ‘hold and kill' mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

Founded in 1944, NSF is committed to protecting and improving human health and the environment on a global scale. NSF is an independent organization that facilitates standards development, product certification, testing, auditing, education and risk management for public health and the environment. Manufacturers, regulators and consumers alike look to NSF for the development of public health standards and certification that help protect the world's food, water, health and consumer products. Widely recognized for its scientific and technical expertise in the health and environmental sciences, NSF is a Pan American Health Organization/World Health Organization Collaborating Center on Food Safety, Water Quality and Indoor Environment. NSF operates more than 320,000 square feet of state-of-the-art laboratory space and serves 40,000 clients in more than 180 countries worldwide. Its 3,000 team members include microbiologists, toxicologists, chemists, engineers, and environmental and public health professionals. Visit us at www.nsf.org.

Portage Biotech is a clinical-stage immuno-oncology company with a team of scientists, clinicians, and pharma-experienced executives who have a long history of success, collectively contributing to five oncology drug approvals. The company is focused on advancing multi-targeted therapies with the mission to expand the number of treatment options for cancer patients.

Purdue Pharma’s bankruptcy case was heard before the Supreme Court of the United States in December 2023. In June 2024, the Court voted 5-4 against third-party releases contained in the Plan of Reorganization. The decision does nothing to deter us from the twin goals of using settlement dollars for opioid abatement and turning the company into an engine for good. We are reaching back out to creditors and renewing our pursuit of a resolution that delivers billions of dollars of value for opioid abatement and allows the Company to emerge from bankruptcy as a company with a public-minded mission. The Supreme Court’s decision does not affect Purdue’s operational stability or our ability to produce medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners and customers. The company will continue serving patients who rely on our medicines, and working to introduce new medicines that will help save and improve lives.

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.

Recombinant Technologies, LLC, is an emerging biotechnology company focused on developing therapeutics for neurodegenerative diseases. This innovative Bio-Technology company will ... Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South ... Recombinant Technologies and life sciences research enabler and commercialization expert.

Spun out of Yale University in 2020, RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies, and advancing complimentary targeted delivery systems, for the broad-spectrum treatment of viral diseases and cancer. Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune’s products act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance the patients’ intrinsic response to disease. RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD, who are also Scientific Advisors for the company. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on RIG-I. Pyle is also a specialist in RNA structure, and design. In collaboration with Iwasaki, Pyle designed the stem loop RNAs for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Thetis Pharmaceuticals is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory disorders. The company was founded in 2011 by ex-Pfizer R&D executives and healthcare investors.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.

TriRx Pharmaceutical Services is a leading global contract development and manufacturing organization (CDMO) that provides comprehensive solutions for the animal health and human pharmaceutical industries. TriRx provides integrated development, manufacturing, and supply services from our network of state-of-the-art facilities across the United States and Europe. Founded by industry veterans, TriRx understands what it means to outsource development and manufacturing of your drug product, and that we are committed to delivering CDMO services at a higher standard of performance. Built on honesty, openness, and integrity, TriRx gives our clients total access to our people and processes, treating your product like its own. TriRx is your partner for advancing products to market. We provide comprehensive development, manufacturing, and packaging capabilities from the clinical- to commercial-scale for both sterile and non-sterile pharmaceutical drug products. Our expertise spans a wide range of services and modalities including: - Biologics - Biotech API - Solid Dose - Drug Development - Analytical Testing - Solutions, Suspensions, and Colloidal Dispersions - Liquids, Creams, Ointments - Fill/Finish - Packaging - Aseptic Compounding - Animal Health Products TriRx maintains strict adherence to the regulatory standards required by the FDA, EMA, and other global health authorities. This, coupled with our rigorous quality control processes, ensures that every product we manufacture meets the highest quality standards. We are more than just a CDMO; we are a trusted partner in the pharmaceutical industry. Whether you are a startup biotech or a multinational pharmaceutical company, TriRx is dedicated to helping you achieve your objectives and bring vital medications to the markets and patients who need them most. Your Product. Your Facility. Your Team. A CDMO You Can Trust.

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.